Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M22.4Revenue $M0.0Net Margin (%)-607,360.0Altman Z-Score-12.3
Enterprise Value $M-3.8EPS $-1.3Operating Margin %-607,360.0Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.1Pre-tax Margin (%)-607,360.0Higher ROA y-yN
Price/Book0.910-y EBITDA Growth Rate %-14.6Quick Ratio10.6Cash flow > EarningsY
Price/Sales4,4675-y EBITDA Growth Rate %-12.9Current Ratio10.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-75.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-80.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 0.92-89%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 0.92-94%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.18-23.73view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-90.44view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-90.45view
Masterson Nola EDirector 2014-09-15Buy200$14.34-93.72view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-93.53view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-93.5view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-93.99view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-95.01view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-94.97view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-96.21view

Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
    Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
    Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

    More From Other Websites
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 08 2016
    4:02 pm Repros Therapeutics holds meeting with FDA to discuss complete response letter for... Feb 08 2016
    Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment... Feb 08 2016
    Smart Money Highlights Oversold Stocks in Small Cap Biotechs Jan 19 2016
    Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company Jan 11 2016
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
    Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company Jan 11 2016
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 06 2016
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2016
    Repros Updates Enclomiphene Program Jan 04 2016
    Repros Provides Update on Proellex Program, Data by 3Q16 Dec 22 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 21 2015
    Repros Updates Proellex® Program Dec 21 2015
    Is Evolution Petroleum Corporation (EPM) Going to Burn These Hedge Funds? Dec 09 2015
    REPROS THERAPEUTICS INC. Financials Dec 08 2015
    The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead Dec 03 2015
    Repros Hits 52-Week Low after Enclomiphene Receives CRL Dec 02 2015
    Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved Dec 02 2015
    Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results Dec 01 2015
    Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene Dec 01 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK